Key Points: TPM® Oxymorphone Patch pre-IND, FDA face-to-face...

Key Points:

TPM® Oxymorphone Patch pre-IND, FDA face-to-face meeting confirmed for December ‘18.

Injectable candidates continue to progress – development candidates on track for 2018 Tox

Multiple companies undertaking due diligence on Animal Health Business.

Strong Vital ET sales on forecast for 2018

Independent research coverage rates POH a ‘Buy’ with target 8-9 cents share price

Mylan Arbitration Outcome: still to come

..for those interested in more than a quick buck, look  no further!